We are live on
!
Find out more
FCOMV
Foresite Capital Opportunity Management V Portfolio holdings
AUM
$33.3M
1-Year Est. Return
47.04%
This Fund
S&P 500
This Quarter
Est. Return
-22.14%
1 Year Est. Return
-47.04%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$39.7M
AUM Growth
-$31.7M
(-44%)
Cap. Flow
-$4.95M
Cap. Flow
% of AUM
-12.48%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
2
Reduced
1
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
+$4.05M |
| 2 |
Hims & Hers Health
HIMS
|
+$1.31M |
| 3 |
Compass Therapeutics
CMPX
|
+$986K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HLTH
Cue Health Inc. Common Stock
HLTH
|
+$4.14M |
| 2 |
Quantum-Si Incorporated
QSI
|
+$3.69M |
| 3 |
Cullinan Oncology
CGEM
|
+$3.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PRDS
1
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $16M | 40.44% |
5,227,307
| – | – |
|
|
THRX
2
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $5.3M | 13.37% |
959,275
+490,455
| +105% | +$4.05M |
|
|
3
Compass Therapeutics
CMPX
$432M
| $4.12M | 10.38% |
1,554,250
+454,250
| +41% | +$986K |
|
4
Disc Medicine
IRON
$3.07B
| $4.12M | 10.37% |
81,171
| – | – |
|
|
KNTE
5
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $3.68M | 9.27% |
291,667
| – | – |
|
6
Adicet Bio
ACET
$84.8M
| $2.48M | 6.26% |
10,625
| – | – |
|
|
7
Quantum-Si Incorporated
QSI
$171M
| $1.47M | 3.7% |
633,626
-964,499
| -60% | -$3.69M |
|
|
8
Hims & Hers Health
HIMS
$6.73B
| $1.39M | 3.5% |
+306,431
| New | +$1.31M |
|
9
Enanta Pharmaceuticals
ENTA
$396M
| $1.07M | 2.71% |
22,750
| – | – |
|
|
10
Cullinan Oncology
CGEM
$1.4B
| – | – |
-330,836
| Closed | -$3.46M |
|
|
HLTH
11
DELISTED
Cue Health Inc. Common Stock
HLTH
| – | – |
-641,483
| Closed | -$4.14M |
|
Similar funds
SHI
SAM
LUGPSI
VCA
KXA
PGM
ACM
KCM
Foresite Capital Opportunity Management V's Q2 2022 Portfolio in Review
As of Q2 2022, Foresite Capital Opportunity Management V held 11 positions worth $39.7M, down 44% from $71.4M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Foresite Capital Opportunity Management V withdrew a net $4.95M in Q2 2022, closing 2 positions and reducing 1 holding. Its most notable exit was Cue Health Inc. Common Stock, an estimated $4.14M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Foresite Capital Opportunity Management V opened a new position in Hims & Hers Health worth $1.39M.
- Foresite Capital Opportunity Management V's largest Q2 2022 buy was Hims & Hers Health: 306,431 shares worth $1.39M.
- Foresite Capital Opportunity Management V added most to Theseus Pharmaceuticals, Inc. Common Stock in Q2 2022, an estimated $4.05M increase.
- Foresite Capital Opportunity Management V's biggest Q2 2022 reduction was Quantum-Si Incorporated, cutting an estimated $3.69M.
- Foresite Capital Opportunity Management V fully exited Cue Health Inc. Common Stock in Q2 2022, selling an estimated $4.14M.
- Foresite Capital Opportunity Management V's ten largest holdings make up 100% of its $39.7M portfolio in Q2 2022.
- Foresite Capital Opportunity Management V opened 1 new position and closed 2 in Q2 2022.
- Foresite Capital Opportunity Management V's portfolio value fell 44% quarter-over-quarter to $39.7M.
Based on Foresite Capital Opportunity Management V's 13F filing for Q2 2022, filed 12 Aug 2022.